Minimally invasive epicardial left-ventricular lead implantation and simultaneous left atrial appendage closure

Johannes Petersen; Yousuf Alassar; Yalin Yildirim; Tobias Tönnis; Hermann Reichenspurner; Simon Pecha

doi:10.3389/fcvm.2023.1129410

Minimally invasive epicardial left-ventricular lead implantation and simultaneous left atrial appendage closure

Front Cardiovasc Med. 2023 Mar 10:10:1129410. doi: 10.3389/fcvm.2023.1129410. eCollection 2023.

Authors

Johannes Petersen^{1

2}, Yousuf Alassar¹, Yalin Yildirim¹, Tobias Tönnis³, Hermann Reichenspurner^{1

2}, Simon Pecha^{1

2}

Affiliations

¹ Department of Cardiovascular Surgery, University Heart and Vascular Center Hamburg, Hamburg, Germany.
² German Center for Cardiovascular Research (DZHK), Hamburg/Kiel/lübeck, Germany.
³ Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany.

Abstract

Background: Atrial fibrillation (AF) is common in patients with heart failure resulting in a high prevalence of AF in patients receiving Cardiac Resynchronization Therapy (CRT) implantation. In patients, unsuitable for transvenous left ventricular (LV)-lead implantation, epicardial LV-lead implantation represents a valuable alternative. Epicardial LV-lead placement can be achieved totally thoracoscopical or via minimally invasive left lateral thoracotomy. In patients with atrial fibrillation, concomitant left atrial appendage (LAA) clipping is feasible via the same access. Therefore, the aim of our study was the analysis of safety and efficacy of epicardial LV lead implantation and concomitant LAA clipping via minimally invasive left-lateral thoracotomy.

Methods: Between December 2019 and March 2022, 8 patients received minimally invasive left atrial LV-lead implantation with concomitant LAA closure using the AtriClip. Transesophageal echocardiography (TEE) was performed to intraoperatively guide and control LAA closure.

Results: Mean patients age was 64 ± 11.2 years, 67% were male patients. Minimally invasive left-lateral thoracotomy was used in 6 patients while a totally thoracoscopic approach was performed in 2 cases. Epicardial lead implantation was successfully performed in all patients with good pacing threshold (mean 0.8 ± 0.2 V) and sensing values (10.1 ± 2.3 mV). Posterolateral position of the LV lead was achieved in all patients. Furthermore, successful LAA closure was confirmed during TEE in all patients. No procedure-related complications occurred in any of the patients. Two patients additionally received simultaneous laser lead extraction during the same procedure. Complete lead extraction was achieved in both patients. All patients were extubated in the OR and had an uneventful postoperative course.

Conclusion: Our study highlights a novel treatment approach for patients with atrial fibrillation and the necessity of epicardial LV leads. Placement of a posterolateral LV lead position with concomitant occlusion of the left atrial appendage via a minimally-invasive left-lateral thoracotomy or even a totally thoracoscopic approach is safe and feasible with superior cosmetic result and complete occlusion of the left atrial appendage.

Keywords: atrial fibrillation; epicardial lead placement; left atrial appendage closure; minimally-invasive; totally thoracoscopic.